Anita Lam
Optometrist · Seattle, WANPI 1417933250
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 37.1% of the total. 2025 is the largest year on record at $15,654, more than ten times the $283 reported in 2019. Among optometrist clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 279 payments — averaging $108.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$11K
- Coopervision Inc.$10K
- Biotissue Holdings Inc.$3K
- Tarsus Pharmaceuticals, Inc.$2K
- Dompe US, Inc.$1K
- Alcon$732
- plus $3K from 16 others
What the payments were for
- Consulting fees$3251%
- Speaking & faculty fees$13,29044%
- Travel & lodging$4,15214%
- Food & beverage$12,42841%
- Gifts$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 74 | $11,214 |
| Coopervision Inc. | 23 | $9,547 |
| Biotissue Holdings Inc. | 22 | $2,752 |
| Tarsus Pharmaceuticals, Inc. | 30 | $1,788 |
| Dompe US, Inc. | 44 | $1,336 |
| Alcon | 16 | $732 |
| Sun Pharmaceutical Industries Inc. | 28 | $686 |
| Lumenis BE Inc | 1 | $575 |
| Oyster Point Pharma, Inc. | 6 | $332 |
| Glaukos Corporation | 2 | $233 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $230 |
| Thea Pharma Inc. | 11 | $221 |
| Mallinckrodt Hospital Products Inc. | 2 | $142 |
| Mallinckrodt Enterprises LLC | 1 | $125 |
| Johnson & Johnson Vision Care, Inc. | 6 | $119 |
| AbbVie | 2 | $39 |
| Sight Sciences, Inc. | 2 | $37 |
| Rxsight Inc | 1 | $33 |
| Kala Pharmaceuticals, Inc. | 1 | $22 |
| Amgen | 1 | $19 |
| Carl Zeiss Meditec, Inc. | 1 | $15 |
| Apellis Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIEBO$9,253
- SynergEyes contact lens$8,646
- XIIDRA$8,597
- XDEMVY$785
- optilight$575
- LOTEMAX SM$251
- ACTHAR$250
- Onefit Contact Lens$226
- Photrexa Viscous and Photrexa$169
- TYRVAYA$163
- LIPIFLOW SYSTEM ACTIVATOR (DISPOSABLE)$145
- Clareon PanOptix Pro$140
- Oxervate$125
- AcrySof IQ PanOptix UV IOL$121
- Clareon$115
- Prokera$108
- AmnioGraft$108
How this compares
$30,209 in reported general payments places this provider in the 95th percentile of 1,267 optometrist providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 17 | $792,493 |
| RestasisCyclosporine | 61 | $55,477 |
| XiidraLifitegrast | 31 | $33,674 |
| MieboPerfluorohexyloctane/Pf | 40 | $31,891 |
| XdemvyLotilaner | 11 | $20,086 |
| CequaCyclosporine | 17 | $11,975 |
| Loteprednol Etabonate | 91 | $11,229 |
| Fluorometholone | 40 | $3,675 |
| Prednisolone Acetate | 33 | $1,207 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 28 | $1,082 |
| Doxycycline Hyclate | 18 | $696 |
| ErythromycinErythromycin Base | 61 | $683 |
| Doxycycline Monohydrate | 15 | $297 |
| Latanoprost | 48 | $264 |
| Timolol Maleate | 16 | $93 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $1,336 | $792,49317 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $11,214 | $65,56571 claims |
| AbbVieRestasis | $39 | $55,47761 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $1,788 | $20,08611 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $686 | $11,97517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,267 optometrist providers in Washington.
Other optometrist in Seattle
- Roya HabibiSeattle$109K
- Huy HoangSeattle$11K
- Jemimah CorpuzSeattle$8K
- Sathi MaitiSeattle$7K
- Leslie LungSeattle$7K
- Gregory ChinSeattle$6K
- Leigh KimSeattle$6K
- Steve BirdSeattle$5K
- Kerri SvandaSeattle$5K
- David KadingKirkland$397K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.